Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intellia Therapeutics Inc    NTLA

INTELLIA THERAPEUTICS INC

(NTLA)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2019 05/20/2019 05/21/2019 05/22/2019 05/23/2019 Date
15.55(c) 14.97(c) 15.78(c) 14.81(c) 14.42(c) Last
349 133 477 578 404 218 423 079 622 857 Volume
-3.54% -3.73% +5.41% -6.15% -2.63% Change
More quotes
Financials (USD)
Sales 2019 30,4 M
EBIT 2019 -114 M
Net income 2019 -110 M
Finance 2019 243 M
Yield 2019 -
Sales 2020 34,6 M
EBIT 2020 -142 M
Net income 2020 -142 M
Finance 2020 179 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 15,7x
EV / Sales2020 15,7x
Capitalization 721 M
More Financials
Company
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair... 
More about the company
Surperformance© ratings of Intellia Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INTELLIA THERAPEUTICS INC
05/22INTELLIA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holder..
AQ
05/02INTELLIA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
AQ
05/02Intellia Therapeutics Announces First Quarter 2019 Financial Results and Comp..
GL
04/29Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data a..
GL
04/25Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 E..
GL
04/16INTELLIA THERAPEUTICS : Announces Three Oral Presentations on In Vivo and Engine..
AQ
04/15Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engin..
GL
04/05INTELLIA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8..
AQ
03/01Intellia CEO not involved in Starboard's Bristol-Myers board challenge
RE
02/28INTELLIA THERAPEUTICS : Announces Fourth Quarter and Full-Year 2018 Financial Re..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart INTELLIA THERAPEUTICS INC
Duration : Period :
Intellia Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 32,1 $
Spread / Average Target 103%
EPS Revisions
Managers
NameTitle
John M. Leonard President, Chief Executive Officer & Director
Perry A. Karsen Chairman
Jose E. Rivera Executive Vice President & General Counsel
Glenn Goddard Chief Financial Officer & Executive Vice President
Jean-Francois B. Formela Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INTELLIA THERAPEUTICS INC5.64%721
IQVIA HOLDINGS INC16.05%26 592
LONZA GROUP25.17%23 527
CELLTRION, INC.--.--%19 888
INCYTE CORPORATION24.26%16 945
EXACT SCIENCES CORPORATION50.41%12 257